TCIM
AKBA icon

TIAA CREF Investment Management’s Akebia Therapeutics AKBA Stock Holding History

TIAA CREF Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.01M Sell
489,801
-24,279
-5% -$167K ﹤0.01% 1586
2018
Q4 		$2.84M Buy
514,080
+28,330
+6% +$222K ﹤0.01% 1743
2018
Q3 		$4.29M Buy
485,750
+19,263
+4% +$172K ﹤0.01% 1663
2018
Q2 		$4.66M Buy
466,487
+246,218
+112% +$2.47M ﹤0.01% 1644
2018
Q1 		$2.1M Sell
220,269
-28,300
-11% -$396K ﹤0.01% 2070
2017
Q4 		$3.7M Sell
248,569
-27,215
-10% -$451K ﹤0.01% 1791
2017
Q3 		$5.42M Buy
275,784
+23,661
+9% +$364K ﹤0.01% 1570
2017
Q2 		$3.62M Buy
252,123
+148,940
+144% +$1.89M ﹤0.01% 1803
2017
Q1 		$949K Sell
103,183
-2,742
-3% -$26.8K ﹤0.01% 2529
2016
Q4 		$1.1M Sell
105,925
-3,340
-3% -$28.8K ﹤0.01% 2476
2016
Q3 		$989 Sell
109,265
-2,377
-2% -$20.2K ﹤0.01% 2549
2016
Q2 		$835K Buy
111,642
+19,550
+21% +$171K ﹤0.01% 2609
2016
Q1 		$830K Buy
92,092
+7,954
+9% +$64.5K ﹤0.01% 2584
2015
Q4 		$1.09M Hold
84,138
– – ﹤0.01% 2528
2015
Q3 		$813K Sell
84,138
-5,257
-6% -$48.2K ﹤0.01% 2690
2015
Q2 		$920K Buy
89,395
+60,458
+209% +$516K ﹤0.01% 2733
2015
Q1 		$321K Hold
28,937
– – ﹤0.01% 3002
2014
Q4 		$337K Sell
28,937
-905
-3% -$13K ﹤0.01% 3043
2014
Q3 		$660K Hold
29,842
– – ﹤0.01% 2854
2014
Q2 		$829K Buy
+29,842
New +$718K ﹤0.01% 2830

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

TIAA CREF Investment Management's AKBA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Akebia Therapeutics (AKBA) stake by 4.7% in Q1 2019, selling an estimated $167K and leaving 489,801 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

TIAA CREF Investment Management first reported a position in AKBA in Q2 2014 and has held it in 20 quarters since. The position peaked at $5.42M in Q3 2017. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

  • TIAA CREF Investment Management held 489,801 shares of Akebia Therapeutics worth $4.01M as of Q1 2019.
  • TIAA CREF Investment Management sold 24,279 Akebia Therapeutics shares in Q1 2019, an estimated $167K.
  • Akebia Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1586 holding.
  • TIAA CREF Investment Management first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 20 quarters since.
  • TIAA CREF Investment Management's Akebia Therapeutics position peaked at $5.42M in Q3 2017.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.